Kraig Biocraft Laboratories, Inc. (KBLB)

Kraig Biocraft Laboratories, Inc. (KBLB) Materials & Commodity Exposure

Kraig Biocraft Laboratories, Inc. specializes in developing and commercializing protein-based fibers, leveraging recombinant DNA technology for applications in technical textiles and specialty fibers. Targeting diverse sectors including defense, industrial, and medical, the company aims to disrupt traditional material science with innovative, high-performance solutions.

What Is the Investment Thesis for KBLB?

Kraig Biocraft Laboratories presents a high-risk, high-reward investment opportunity centered on its proprietary spider silk technology. The company's potential lies in disrupting the technical textile and specialty fiber markets with a sustainable, high-performance alternative to traditional materials. Key value drivers include successful scaling of spider silk production, securing significant contracts in target markets such as defense and aerospace, and achieving profitability. However, the company's negative profit margin of -13698.5% and negative gross margin of -15.1% highlight significant financial challenges. Upcoming catalysts include potential advancements in production efficiency and new partnerships. Investors should closely monitor the company's ability to secure funding and achieve commercial viability.

Based on FMP financials and quantitative analysis

KBLB Key Highlights

• Market capitalization of $119.10M indicates a small-cap company with potential for growth but also higher volatility.
• P/E ratio of -35.29 reflects the company's current lack of profitability, suggesting it is an early-stage growth company.
• Profit Margin of -13698.5% highlights significant operational inefficiencies and challenges in achieving profitability.
• Gross Margin of -15.1% indicates that the company's cost of goods sold exceeds its revenue, requiring substantial improvements in production efficiency.
• Beta of 1.33 suggests the stock is more volatile than the market, indicating higher risk and potential for larger price swings.

Who Are KBLB's Competitors?

KBLB is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KBLB's Key Strengths?

• Proprietary spider silk technology.
• Potential for high-performance materials.
• Sustainable and eco-friendly production process.
• Diverse range of potential applications.

What Are KBLB's Weaknesses?

• Negative profit margin and gross margin.
• Limited commercial production capacity.
• Reliance on successful scaling of production.
• Competition from established material companies.

What Could Drive KBLB Stock Higher?

• Potential advancements in spider silk production efficiency.
• Securing new contracts in the defense or aerospace sectors.
• Research and development efforts to expand applications of spider silk.
• Partnerships with industry leaders to commercialize spider silk products.
• Efforts to improve financial performance and achieve profitability.

What Are the Key Risks for KBLB?

• Financial-distress signal — its Altman Z-Score of -20.38 sits in the distress zone (elevated bankruptcy risk).
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Negative profit margin and gross margin indicate financial instability.
• Competition from established material companies.
• Technological advancements by competitors.
• Regulatory hurdles and compliance requirements.
• Reliance on successful scaling of spider silk production.

What Are the Growth Opportunities for KBLB?

• Growth opportunity 1: Expansion into the defense and military textiles market represents a significant growth opportunity for Kraig Biocraft. Spider silk's exceptional strength and ballistic protection capabilities make it an ideal material for body armor and other protective gear. Securing contracts with defense agencies could drive substantial revenue growth. The global military textiles market is projected to reach billions of dollars, offering a large addressable market for Kraig Biocraft. Timeline: Ongoing.
• Growth opportunity 2: Penetration of the aerospace composite materials market offers another avenue for growth. Spider silk can be used to reinforce composite materials, enhancing their strength and durability while reducing weight. This is particularly valuable in the aerospace industry, where weight reduction translates to fuel efficiency and improved performance. The aerospace composite materials market is expected to grow, driven by increasing demand for lightweight and fuel-efficient aircraft. Timeline: Ongoing.
• Growth opportunity 3: Development of medical textile applications for spider silk presents a high-value growth opportunity. Spider silk's biocompatibility and strength make it suitable for sutures, wound dressings, and tissue scaffolds. The medical textiles market is growing, driven by advancements in healthcare technology and increasing demand for biocompatible materials. Kraig Biocraft can partner with medical device companies to develop and commercialize spider silk-based medical products. Timeline: Ongoing.
• Growth opportunity 4: Licensing of Kraig Biocraft's spider silk technology to other companies in the textile and materials industries could generate significant revenue streams. Licensing agreements would allow other companies to utilize Kraig Biocraft's technology to develop and commercialize their own spider silk-based products. This strategy would expand the reach of Kraig Biocraft's technology and generate recurring revenue. Timeline: Ongoing.
• Growth opportunity 5: Improving production efficiency and scaling up spider silk production is crucial for achieving profitability and meeting market demand. Investing in research and development to optimize silkworm breeding and silk extraction processes can significantly reduce production costs and increase output. This will enable Kraig Biocraft to compete more effectively with traditional materials and capture a larger share of the market. Timeline: Ongoing.

What Opportunities Does KBLB Have?

• Expansion into defense, aerospace, and medical markets.
• Licensing of spider silk technology.
• Partnerships with industry leaders.
• Increasing demand for sustainable materials.

What Threats Does KBLB Face?

• Competition from alternative materials.
• Technological advancements by competitors.
• Regulatory hurdles and compliance requirements.
• Economic downturn affecting demand for specialty materials.

What Are KBLB's Competitive Advantages?

• Proprietary recombinant DNA technology for spider silk production.
• Patents protecting its spider silk technology.
• First-mover advantage in the spider silk market.
• Potential for strong brand recognition as a leader in advanced materials.

What Does KBLB Do?

Kraig Biocraft Laboratories, Inc., founded in 2006 and headquartered in Ann Arbor, Michigan, is a biotechnology company focused on the development and commercialization of protein-based fibers. The company utilizes recombinant DNA technology to create advanced materials with unique properties, targeting the technical textile and specialty fiber industries. Kraig Biocraft's core innovation lies in genetically engineering silkworms to produce spider silk, a material known for its exceptional strength, elasticity, and toughness. These spider silk-based fibers are designed for a wide range of applications, including ballistic protection, industrial cables, safety equipment, and composite materials for the aerospace industry. The company's products also cater to niche markets such as medical textiles, geotextiles, defense and military textiles, protective clothing, filtration textiles, and functional textiles for buildings and transportation. Kraig Biocraft aims to replace traditional materials with sustainable, high-performance alternatives, positioning itself as a key player in the advanced materials sector.

What Products and Services Does KBLB Offer?

• Develops protein-based fibers using recombinant DNA technology.
• Engineers silkworms to produce spider silk.
• Creates advanced materials with unique properties.
• Targets the technical textile and specialty fiber industries.
• Offers spider silk-based fibers for ballistic protection.
• Provides materials for industrial cables and safety equipment.
• Develops composite materials for the aerospace industry.

How Does KBLB Make Money?

• Develops and patents recombinant DNA technology for spider silk production.
• Produces spider silk fibers through genetically engineered silkworms.
• Sells spider silk fibers to manufacturers in various industries.
• Potentially licenses its technology to other companies for revenue.

What Industry Does KBLB Operate In?

Kraig Biocraft Laboratories operates within the specialty chemicals industry, a sector characterized by innovation in material science and increasing demand for high-performance and sustainable materials. The technical textile market, a key target for Kraig Biocraft, is projected to grow, driven by advancements in material technology and increasing applications in defense, aerospace, and healthcare. Competition includes established chemical companies and emerging biotech firms focused on advanced materials. Kraig Biocraft aims to differentiate itself through its proprietary spider silk technology, offering a unique combination of strength, elasticity, and sustainability.

Who Are KBLB's Key Customers?

• Manufacturers of ballistic protection equipment.
• Companies producing industrial cables and safety equipment.
• Aerospace companies using composite materials.
• Medical device companies requiring biocompatible materials.

F-Score 1/9Financial Health

Kraig Biocraft Laboratories, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -20.38 places it in the distress zone, a signal of elevated financial risk.

ROE 50%Key Financial Metrics

Return on equity for Kraig Biocraft Laboratories, Inc. stands at 50.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.28 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -3.6%, the inverse of the P/E and a quick read on earnings relative to price.

Kraig Biocraft Laboratories, Inc. (KBLB) Valuation Context

Valued at $119.10M, KBLB is classified as a micro-cap stock. Relative to its peer group, KBLB's quantitative score of 44/100 is roughly in line with the peer average of 50/100.

KBLB Financials

KBLB Latest News

KBLB Analyst Consensus

KBLB MoonshotScore

What Investors Ask About Kraig Biocraft Laboratories, Inc. (KBLB) — Basic Materials

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources